Safe Pro Group (NASDAQ:SPAI) vs. Burning Rock Biotech (NASDAQ:BNR) Head-To-Head Contrast

Safe Pro Group (NASDAQ:SPAI) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Volatility and Risk

Safe Pro Group has a beta of 3.71, meaning that its stock price is 271% more volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Insider and Institutional Ownership

30.0% of Burning Rock Biotech shares are held by institutional investors. 54.8% of Safe Pro Group shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Safe Pro Group and Burning Rock Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Safe Pro Group	-968.74%	-280.18%	-224.48%
Burning Rock Biotech	-22.33%	-21.26%	-14.27%

Analyst Ratings

This is a breakdown of recent ratings for Safe Pro Group and Burning Rock Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Safe Pro Group	2	0	1	2	2.60
Burning Rock Biotech	1	0	0	0	1.00

Safe Pro Group presently has a consensus price target of $10.00, suggesting a potential upside of 150.06%. Given Safe Pro Group’s stronger consensus rating and higher probable upside, equities analysts plainly believe Safe Pro Group is more favorable than Burning Rock Biotech.

Valuation and Earnings

This table compares Safe Pro Group and Burning Rock Biotech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Safe Pro Group	$2.17 million	38.64	-$7.43 million	($0.75)	-5.33
Burning Rock Biotech	$70.67 million	3.96	-$47.49 million	($1.66)	-15.67

Safe Pro Group has higher earnings, but lower revenue than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Safe Pro Group, indicating that it is currently the more affordable of the two stocks.

Summary

Safe Pro Group beats Burning Rock Biotech on 10 of the 15 factors compared between the two stocks.

About Safe Pro Group

Safe Pro Group, Inc. engages in the provision and acquisition of security and protection products. Its products include Artificial Intelligence (AI) and Machine Learning (ML) software technology and photogrammetry analysis tools, bullet and blast resistant personal protection equipment, and aerial managed services and mission-critical uncrewed solutions. The firm operates through the following segments: Safe-PRO USA, Airborne Response, and Safe Pro AI. The company was founded by Daniyel Erdberg on December 15, 2021 and is headquartered in Aventura, FL.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.